ALPHAMAB ONCOLO.DL-000002

Research ALPHAMAB ONCOLO.DL-000002 (3NK) on Bullrun: market cap EUR 745.87M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker3NK
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 745.87M
• Financial periodFY2025
• RevenueEUR 566.24M
• Revenue growth-11.5%
• Net income-EUR 113.94M
• Free cash flow-EUR 153.48M
• Gross margin88.8%

Valuation Snapshot

latest market cap is EUR 745.87M.

About ALPHAMAB ONCOLO.DL-000002

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand.

Frequently asked questions

What is ALPHAMAB ONCOLO.DL-000002's market cap?

ALPHAMAB ONCOLO.DL-000002's market capitalization is EUR 745.87M.

What does ALPHAMAB ONCOLO.DL-000002 do?

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China.